看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 2.2x - 2.4x | 2.3x |
| Selected Fwd Ps Multiple | 0.4x - 0.4x | 0.4x |
| Fair Value | $0.36 - $0.40 | $0.38 |
| Upside | 43.0% - 58.0% | 50.5% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Medicine Man Technologies, Inc. | - | OTCPK:SHWZ |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| ProPhase Labs, Inc. | - | NasdaqCM:PRPH |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT.F | HRMY | EOLS | SHWZ | TARS | PRPH | |||
| OTCPK:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | OTCPK:SHWZ | NasdaqGS:TARS | NasdaqCM:PRPH | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 91.7% | 160.2% | 50.1% | 85.2% | NM- | -7.3% | ||
| 3Y CAGR | 19.1% | 32.8% | 38.8% | 93.0% | 47.5% | -55.9% | ||
| Latest Twelve Months | -27.5% | 22.8% | 31.8% | 5.5% | 948.6% | -80.6% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | -20.1% | -93.5% | -44.9% | -276.4% | -65.5% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -16.5% | -778.9% | -46.8% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -24.8% | -63.2% | -731.5% | ||
| Latest Twelve Months | -46.6% | 20.4% | -18.9% | -38.8% | -63.2% | -731.5% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -13.2x | 5.9x | -31.9x | 16.4x | -14.8x | -1.1x | ||
| Price / LTM Sales | 0.1x | 2.3x | 2.5x | 0.0x | 10.8x | 1.5x | ||
| LTM P/E Ratio | -0.2x | 11.5x | -13.0x | 0.0x | -17.2x | -0.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.0x | 2.3x | 10.8x | |||||
| Historical LTM P/S Ratio | 1.1x | 1.5x | 8.5x | |||||
| Selected Price / Sales Multiple | 2.2x | 2.3x | 2.4x | |||||
| (x) LTM Sales | 7 | 7 | 7 | |||||
| (=) Equity Value | 15 | 16 | 16 | |||||
| (/) Shares Outstanding | 41.9 | 41.9 | 41.9 | |||||
| Implied Value Range | 0.35 | 0.37 | 0.39 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.35 | 0.37 | 0.39 | 0.25 | ||||
| Upside / (Downside) | 40.8% | 48.2% | 55.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | SHWZ | TARS | PRPH | |
| Value of Common Equity | 7 | 1,613 | 595 | 1 | 1,982 | 10 | |
| (/) Shares Outstanding | 916.4 | 57.3 | 63.6 | 80.2 | 44.4 | 41.9 | |
| Implied Stock Price | 0.01 | 28.13 | 9.36 | 0.01 | 44.63 | 0.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.01 | 28.13 | 9.36 | 0.01 | 44.63 | 0.25 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |